 CEO, PRESIDENT EVOLUS INC.
WHY: Runs neurotoxin upstart, maker of Jeuveau, touted as a cheaper, more effective version of Allergan’s Botox. Held senior marketing roles with Allergan for more than a decade, including SVP of medical aesthetics, before joining Evolus in 2018.
RECENT: Secured $40M investment from South Korean pharmaceutical firm and partner Daewoong Pharmaceutical in July.
QUOTABLE: Jeuveau “exists to bring options and choice back to the market,” which hasn’t “seen a new market entrant in nearly a decade.”
